Click here to close Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly. We suggest using a current version of Chrome, FireFox, or Safari.
Search Criteria
Gene/CloneSpeciesStageAnatomy ItemExperimenter
tpm1xenopus   

Too many results?Too few results?

Experiment details for tpm1

Meadows SM et al. (2008) Assay

The myocardin-related transcription factor, MASTR, cooperates with MyoD to activate skeletal muscle gene expression.

Gene Clone Species Stages Anatomy
tpm1.L laevis NF stage 22 to NF stage 23 somite , muscle , skeletal muscle , myotome

Display additional annotations [+]
  Fig. 2. Inhibition of MASTR function reduces expression of skeletal muscle markers. (A–C) Embryos expressing a dominant-negative form of the MASTR protein (DN-MASTR) were assayed at St 22/23 for muscle markers as shown. Injected sides are indicated by arrowheads. (D) Dose-dependent reduction in cardiac α-actin expression after expression of DN-MASTR. (E–G) MO knockdown of MASTR expression results in reduced muscle marker expression as indicated. MO-treated sides are indicated by the arrowheads. (H) Transverse section through the trunk of St 22 embryo treated with MO on the right-hand side and assayed for cardiac α-actin expression. The general structure of the somite is normal, but marker expression is reduced on the treated side. (I) MO-treated embryo shows no reduction in MyoD expression. (J) Two nonoverlapping MO sequences directed against MASTR mRNA (MO1 and MO2) were equally effective in reducing expression of cardiac α-actin. (K) Rescue of the MO-induced phenotype. Embryos were injected with MO2 alone or with MO2 plus MASTR mRNA. Addition of MASTR mRNA achieved partial rescue of MO inhibition in a dose-dependent manner.

Gene Clone Species Stages Anatomy
tpm1.L laevis NF stage 22 somite , muscle , skeletal muscle , myotome

Display additional annotations [+]
  Fig. 3. MASTR induces ectopic expression of muscle markers. (A) Uninjected control embryo at St 22 (lateral view) shows no expression of αMHC marker. (B) Embryo injected with 500 pg of MASTR mRNA shows extensive ectopic expression of αMHC. (C) Control embryo (dorsal view) showing expression of the muscle marker, α-tropomyosin in the somites. (D) Embryo injected with 500 pg of MASTR mRNA shows limited ectopic expression of α-tropomyosin immediately lateral to the somites (arrows). (E and F) Uninjected control embryo (E) and embryo injected with 500 pg of MASTR mRNA (F) assayed for expression of cardiac α-actin. Injected embryo shows extensive ectopic expression of cardiac α-actin. (G) Transverse section through trunk of St 22 embryo injected with MASTR mRNA and assayed for cardiac α-actin transcripts. Arrows indicate that ectopic marker expression is limited to the lateral mesoderm tissue and is absent from epidermis and endodermal tissue. (H) MASTR activates expression of muscle markers in nonmuscle (animal cap) tissue. Embryos were injected with 500 pg of mRNA encoding either myocardin or MASTR, and animal cap explants were isolated and then analyzed by RT-PCR at St 12.5. Myocardin serves as a positive control. Muscle markers are indicated on the left-hand side of the figure. Muscle tissues expressing the various markers are indicated at the right. Lanes labeled St 12.5 WE and St 47 WE are positive control samples from whole embryos at St 12.5 and 47 respectively. ODC transcripts serve as a loading control. (I and J) Mutant MASTR lacking SRF interaction domains (δMASTR) fails to activate muscle marker expression. Experiments were conducted exactly as described for H above but analyzed by quantitative PCR. In the case of both αMHC and α-tropomyosin, a low level of transcript is detected in the untreated animal cap. Results are expressed relative to marker transcripts induced by MASTR.